Mr. Walbert has been a member of our board of directors since March 2014 and has served as our chair since June 2015. Mr. Walbert has been the president and chief executive officer of Horizon Pharma since June 2008 and has been the chairman of the Horizon board since 2010. Previously, he served as president, chief executive officer, and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Mr. Walbert served as executive vice president, commercial operations, at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Mr. Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA, which is on track to exceed $10.0 billion in 2013 sales, and divisional vice president, global cardiovascular strategy, at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America, and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc., and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College. In addition to the Egalet board of directors, Mr. Walbert serves on the XOMA Ltd., Sucampo Pharmaceuticals, Inc., Biotechnology Industry Organization (BIO), Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT and Greater Chicago Arthritis Foundation boards. Mr. Walbert was appointed by Illinois Governor Pat Quinn to the Illinois Innovation Council.
Ms. Hochberg has served as a member of our board of directors since April 2017. Ms. Hochberg has been the managing partner of Elaran, LLC, a business strategy and management firm, since 2016. She served in various positions of increasing responsibility at Forest Laboratories, LLC from 1997 to 2014, including as executive vice president – international, strategic planning and government affairs from 2013 to 2014, as executive vice president – US sales and marketing from 2010 to 2013 and as chief commercial officer from 2007 to 2013. Prior to that, Ms. Hochberg served in various roles at Wyeth Ayerst Laboratories. She serves on the board of Akcea Therapeutics, Inc., as well as the boards of several nonprofit corporations. Ms. Hochberg earned her BA and MBA from Columbia University.
Nicholas Nicolaides, PhD
Dr. Nicolaides has been on our board of directors since joining in April of 2015. He is the president and co-founder of Morphotek, a biopharmaceutical company specializing in the development of protein and antibody products for treating cancer, inflammation and infectious disease. Dr. Nicolaides’ post-graduate research at Johns Hopkins Medical School was the basis for the company’s inception. In the spring of 2007, Morphotek was acquired by Eisai Co. Ltd, a global health care pharmaceutical company. Prior to co-founding Morphotek, Dr. Nicolaides was the director of research at Magainin Pharmaceuticals, where his research focused on the development of bio-therapeutics to treat respiratory disease. He is a trained molecular geneticist and has authored a number of scientific papers on the molecular and genetic basis of cancer and respiratory diseases. He received his B.S. in biology at St. Joseph’s University, his Ph.D. in human genetics at Thomas Jefferson University and continued his training as a Fellow in Oncology at Johns Hopkins University. Dr. Nicolaides is an author on more than 50 original publications and is an inventor on numerous patents for developing bio-based therapies and therapeutic compositions.
Mr. Osborn has been a member of our board of directors since joining in April 2015. An experienced life sciences industry executive, Mr. Osborn was general counsel for a decade with Fortune 1000 biopharmaceutical company Cephalon, Inc. and held senior posts with Onyx Pharmaceuticals, Dendreon, US Oncology and DuPont Merck Pharmaceuticals. He has substantial experience in government affairs and public policy, having served with the U.S. Department of State during the George H.W. Bush administration, and from 2008 to 2011 he was a member of the bipartisan United States Advisory Commission on Public Diplomacy. Mr. Osborn currently is a senior advisor with the international law firm Hogan Lovells, and an industry advisor with the healthcare and consumer group of the global private equity firm Warburg Pincus. He has held faculty appointments at Oxford, Princeton and the University of Washington, and is a member of the Council on Foreign Relations, the American Law Institute, the advisory boards of QPID Health, Inc. and the University of Michigan Life Sciences Institute. Mr. Osborn received his undergraduate degree in economics and history from the University of Iowa, his law degree from the University of Virginia School of Law, and his master’s degree in international public policy from The Johns Hopkins University School of Advanced International Studies.
Mr. Radie is president, chief executive officer and a member of Egalet’s board of directors and has been since March 2012. Mr. Radie has had a successful career with more than three decades in the industry and has been responsible for the sale of five companies. In 2005 Mr. Radie led the sale of Vicuron Pharmaceuticals to Pfizer for $1.9 billion and most recently he was responsible for the sale of Topaz Pharmaceuticals Inc. to Sanofi Pasteur for an undisclosed amount. Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Prestwick Pharmaceuticals, Inc., Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and served as a director of Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014, when a majority of Affinium’s assets were acquired by a third party. Mr. Radie began his career in the life sciences at Eli Lilly and Company where he worked for 18 years in sales and marketing positions with increasing levels of responsibility. Mr. Radie serves on the board of Paratek Pharmaceuticals, a biopharmaceutical company, Pennsylvania Bio, an industry group supporting Pennsylvania life sciences companies, Veloxis, a private commercial-stage company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie received his B.S. in chemistry from Boston College.
Robert P. Roche, Jr.
Mr. Roche has been a member of our board of directors since joining in December 2016. An experienced life sciences industry executive, Mr. Roche is the founding member of Robert Roche Associates LLC, a consulting firm providing guidance to the pharmaceutical and healthcare industries that he created upon his retirement from Cephalon Inc. in February 2010. Mr. Roche joined Cephalon in January 1995 as the vice president, sales and marketing and was named executive vice president, worldwide pharmaceutical operations in 2005 where he was responsible for the establishment, management and leadership of the company’s global commercial activities. Prior to Cephalon, Mr. Roche served as director and vice president, worldwide strategic product development for SmithKline Beecham’s central nervous system and gastrointestinal products business. He also was managing director of SmithKline’s pharmaceutical operations in the Philippines. Prior to that, he held senior marketing positions in Canada and Spain, and had product planning responsibilities for SmithKline in Latin America. Mr. Roche began his pharmaceutical career in 1982 with SmithKline & French as a U.S. pharmaceutical sales representative. In addition to the Egalet board of directors, Mr. Roche is a member of the board of directors of Antares Pharma, Aratana Therapeutics, and Paragon Bioservices, Inc. and Bryn Mawr Hospital. Mr. Roche is a graduate of Colgate University and earned an MBA from The Wharton School at the University of Pennsylvania.
Andrea Heslin Smiley
Ms. Smiley has served as a member of our board of directors since April 2017. Ms. Smiley has served as president and CEO at VMS BioMarketing since 2011. Prior to joining VMS BioMarketing in 2008, Ms. Smiley served in various positions at Eli Lilly and Company. Ms. Smiley has served on the board of numerous nonprofit organizations including the Indiana Alzheimer’s Association, Indiana Salvation Army, and the Lung Force Women’s Cabinet, and she received a gubernatorial appointment to the Indiana Commission for Women. Ms. Smiley earned her BA in economics from DePauw University where she was an Honors Management Fellow.
Mr. Weaver joined our board of directors effective February 5, 2014, the date of the listing of our common stock on the NASDAQ Global Market. As of January 15, 2015 Mr. Weaver serves as executive vice president and chief financial officer of Oryzon Genomics, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases. From September 2013 to October 2014, Mr. Weaver served as the chief financial officer, senior vice president, treasurer and corporate secretary of Fibrocell Science, Inc., a publicly held cell therapy company. From June 2011 to July 2013, Mr. Weaver served as senior vice president and chief financial officer of Celsion Corporation, a publicly held biotechnology company, and was a director and chairman of the audit committee of Celsion’s Board of Directors from 2005 to 2011. From February 2009 to September 2010, Mr. Weaver served as senior vice president and chief financial officer of Poniard Pharmaceuticals, a public oncology drug development company. From February 2007 to February 2009, Mr. Weaver served as chief financial officer of Talyst, Inc., a privately-held pharmacy information product company. In 2006 and 2007, he served as senior vice president and chief financial officer of Sirna Therapeutics, a public RNA therapeutics company until it was acquired by Merck & Co., Inc., in December 2006. From 2002 to 2005, Mr. Weaver was chief financial officer of Nastech Pharmaceuticals, a public drug delivery company. From 1999 to 2002, Mr. Weaver was chief financial officer of Ilex Oncology Inc., a public oncology drug development company, and from 1996 to 1999, he was chief financial officer of Prism Technologies, a privately held medical device company. Prior to that, Mr. Weaver held increasingly senior positions with Fidelity Capital and Arthur Andersen LLP. Mr. Weaver currently serves on the board of directors and audit committee of Atossa Genetics, a publicly held diagnostics company, and also served as a director and chairman of the audit committee of SCOLR Pharmaceuticals, a public drug delivery company, from 2007 to 2009. Mr. Weaver is a certified public accountant and received an M.B.A. from Boston College and a B.S. in accounting from Trinity University.